Table 3.

Median overall survival in subgroups split by treatment arm, 5-FU or gemcitabine (GEM), cytidine deaminase (CDA) mRNA, and human equilibrative nucleotide transporter-1 (hENT1) protein status.

Arm	Biomarker Expression (High or Low)	Number	Median OS	95% Confidence Interval	Log Rank	p-Value
5-FU/FA	CDA High	36	14.6	8.4–24.1	5.17	0.0229
	CDA Low	96	26.4	21.4–29.7
GEM	CDA High	56	21.2	15.7–26.2	5.14	0.0234
	CDA Low	89	24.8	18.3–33.0
5-FU/FA	hENT1 High	59	22.6	17.3–28.6	0.53	0.4658
	hENT1 Low	69	24.1	15.9–30.4
GEM	hENT1 High	82	26.0	21.2–32.8	7.58	0.0059
	hENT1 Low	58	16.8	14.1–24.8
5-FU	CDA Low, hENT1 Low	44	29.3	21.9–41.9	6.14	0.1050
	CDA High, hENT1 Low	25	14.2	7.9–24.1
	CDA Low, hENT1 High	49	22.6	16.9–29.6
	CDA High, hENT1 High	10	20.1	5.0–37.5
GEM	CDA Low, hENT1 Low	34	18.3	13.9–28.3	12.0	0.0073
	CDA High, hENT1 Low	24	14.6	11.1–25.1
	CDA Low, hENT1 High	52	28.0	21.1–45.5
	CDA High, hENT1 High	30	23.8	16.6–28.7

Significant values in bold.